↓ Skip to main content

NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas

Overview of attention for article published in BMC Cancer, October 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas
Published in
BMC Cancer, October 2015
DOI 10.1186/s12885-015-1806-8
Pubmed ID
Authors

Shama Virani, Emily Bellile, Carol R. Bradford, Thomas E. Carey, Douglas B. Chepeha, Justin A. Colacino, Joseph I. Helman, Jonathan B. McHugh, Lisa A. Peterson, Maureen A. Sartor, Jeremy MG Taylor, Heather M. Walline, Greg T. Wolf, Laura S. Rozek

Abstract

HPV-associated HNSCCs have a distinct etiologic mechanism and better prognosis than those with non-HPV associated HNSCCs. However, even within the each group, there is heterogeneity in survival time. Here, we test the hypothesis that specific candidate gene methylation markers (CCNA1, NDN, CD1A, DCC, p16, GADD45A) are associated with tumor recurrence and survival, in a well-characterized, prospective, cohort of 346 HNSCC patients. Kaplan-Meier curves were used to estimate survival time distributions. Multivariable Cox Proportional Hazards models were used to test associations between each methylation marker and OST/RPFT after adjusting for known or identified prognostic factors. Stratified Cox models included an interaction term between HPV and methylation marker to test for differences in the associations of the biomarker with OST or RPFT across HPV status. Methylation markers were differentially associated with patient characteristics. DNA hypermethylation of NDN and CD1A was found to be significantly associated with overall survival time (OST) in all HNSCC patients (NDN hazard ratio (HR): 2.35, 95 % CI: 1.40-3.94; CD1A HR: 1.31, 95 % CI: 1.01-1.71). Stratification by HPV status revealed hypermethylation of CD1A was associated with better OST and recurrence/persistence-free time (RPFT) (OST HR: 3.34, 95 % CI: 1.88-5.93; RPFT HR: 2.06, 95 % CI: 1.21-3.49), while hypomethylation of CCNA1 was associated with increased RPFT in HPV (+) patients only (HR: 0.31, 95 % CI: 0.13-0.74). This study is the first to describe novel epigenetic alterations associated with survival in an unselected, prospectively collected, consecutive cohort of patients with HNSCC. DNA hypermethylation of NDN and CD1A was found to be significantly associated with increased overall survival time in all HNSCC patients. However, stratification by the important prognostic factor of HPV status revealed the immune marker, CD1A, and the cell cycle regulator, CCNA1 to be associated with prognosis in HPV (+) patients, specifically. Here, we identified novel methylation markers and specific, epigenetic molecular differences associated with HPV status, which warrant further investigation.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 22%
Student > Postgraduate 5 11%
Student > Bachelor 4 9%
Professor 4 9%
Researcher 4 9%
Other 6 13%
Unknown 13 28%
Readers by discipline Count As %
Medicine and Dentistry 16 35%
Biochemistry, Genetics and Molecular Biology 8 17%
Agricultural and Biological Sciences 5 11%
Immunology and Microbiology 1 2%
Mathematics 1 2%
Other 1 2%
Unknown 14 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2016.
All research outputs
#3,424,927
of 8,255,097 outputs
Outputs from BMC Cancer
#846
of 3,474 outputs
Outputs of similar age
#84,949
of 243,886 outputs
Outputs of similar age from BMC Cancer
#50
of 239 outputs
Altmetric has tracked 8,255,097 research outputs across all sources so far. This one has received more attention than most of these and is in the 57th percentile.
So far Altmetric has tracked 3,474 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,886 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 239 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.